Seelos Therapeutics (SEEL)

Seelos Therapeutics Company Information

NameSeelos Therapeutics
Headquarters300 Park Avenue
New York, NY 10022. United States
Phone646 293 2100

Seelos Therapeutics Inc is a research and development-based clinical-stage biopharmaceutical brand that was founded in 2016. 

Its main task is to develop and commercialize novel therapeutic and technological treatments of the CNS, respiratory diseases, and orphan conditions.

Seelos is currently conducting the following programs:

Lead programs 

SLS-002 – the study looks into the effectiveness of intranasal-administered ketamine in treating suicidal thoughts and behaviors in people who suffer from depression and PTSD. 

SLS-005 – examines the therapeutic impacts of a protein stabilizer in the treatment of Sanfilippo syndrome

SLS-006 – Looks into a compound that partially binds to the dopamine receptor and how effective it is in treating patients with Parkinson’s Disease.

Pre-clinical programs 

SLS-004 – gene therapy for the treatment of Parkinson’s Disease. 

SLS-007 – studies the impact of an anti-alpha-synuclein peptide inhibitor on patients with Parkinson’s disease. 

SLS-008– looks into the effectiveness of an orally available antagonist for chemoattractant receptor-homologous molecule in treating patients suffering from chronic inflammation in asthma and pediatric orphan conditions.

SLS-010 – investigates an orally administered histamine H2A receptor in the treatment of narcolepsy and other related conditions.

SLS-012: A look into the effectiveness of an injectable therapy that manages pain after an operation/surgery.

Seelos criteria for drug development 

Before Seelos commits itself to conduct research and development, an asset must meet the following criteria must be met:

  • The asset must present a solution to an unmet medical need or orphan population or a novel approach to currently available treatments. 
  • The asset must be supported by numerous and available human data or scientific rationale
  • The assets should be clinically-ready or have minimum requirements to move from the preclinical to clinical stages
  • The clinical development pathway should make sense economic or financial-wise. It should also fit with the size of the Seelos company.

Seelos clinical trials 

Seelos is invested in the development of new treatments for the central nervous system and orphan diseases. The clinical trials it conducts aim at proving the asset’s effectiveness and safety levels. 

Using Seelos criteria of selecting assets for the drug development process ensures that they skip the lengthy, time-consuming, and demanding preclinical stages of research and development.

Working with clinically-ready assets presents the advantage of moving at an accelerated speed towards getting vital data readouts. The company’s goal is to develop novel and effective therapies to facilitate the treatment of well-known diseases.

 It also seeks to offer therapies for orphan conditions, recently diagnosed diseases, and conditions with an unmet medical need.